Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2029

Conditions

Rectal Cancer

Interventions

RADIATION

Radiation

Shor-course radiotherapy: 25Gy/5Fx

DRUG

PD-1 antibody

PD-1 antibody (Toripalimab): 240mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 d1-14 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER